Effect of CL 184,005, a platelet-activating factor antagonist in a murine model of Staphylococcus aureus-induced gram-positive sepsis.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of Infectious Diseases

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/INFDIS/169.1.150PMID 8277176
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The efficacy of combination immunotherapy in experimental Pseudomonas sepsis.

  1993cited by this paper
• Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis

  1992cited by this paper
• Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor.

  1992cited by this paper
• Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody.

  1992cited by this paper
• Tumor Necrosis Factor and Regulation of Metabolism in Infection: Role of Systemic versus Tissue Levels

  1992cited by this paper
• Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide.

  1992cited by this paper
• Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line.

  1992cited by this paper
• Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

  1991cited by this paper
• Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.

  1991cited by this paper
• Tumor necrosis factor-independent IL-6 production during murine listeriosis.

  1991cited by this paper
• Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice

  1991cited by this paper
• Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages.

  1990cited by this paper
• The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells

  1990cited by this paper
• Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF.

  1990cited by this paper
• Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.

  1990cited by this paper
• Platelet-activating factor or a platelet-activating factor antagonist decreases tumor necrosis factor-alpha in the plasma of mice treated with endotoxin.

  1990cited by this paper
• The V beta-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice.

  1989cited by this paper
• Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors.

  1989cited by this paper
• IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.

  1989cited by this paper
• Endotoxin-induced cytokine gene expression in vivo. I. Expression of tumor necrosis factor mRNA in visceral organs under physiologic conditions and during endotoxemia.

  1989cited by this paper
• Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock.

  1989cited by this paper
• A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF.

  1988cited by this paper
• Staphylococcus aureus-induced shock: a pathophysiologic study.

  1988cited by this paper
• Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells.

  1988cited by this paper
• Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor

  1987cited by this paper
• A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

  1987cited by this paper
• Platelet activating factor; chemical and biochemical characteristics.

  1987cited by this paper
• Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas

  1987cited by this paper
• Metabolism of 1-O-alkyl-2-acetyl-sn-glycerol by washed rabbit platelets: formation of platelet activating factor.

  1984cited by this paper
• Role of peptidoglycan from Staphylococcus aureus in leukopenia, thrombocytopenia, and complement activation associated with bacteremia.

  1982cited by this paper
• A rapid method of total lipid extraction and purification.

  1959cited by this paper

• Gilthead seabream (Sparus aurata) fed with polar lipids from olive oil industry by-products: Shelf-life, microbiological and physicochemical characteristics during storage at 2oC

  2024cites this paper
• Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology?

  2013cites this paper
• Treatment of sepsis.

  2012cites this paper
• Antibacterial and anti-PAF activity of lipid extracts from sea bass (Dicentrarchus labrax) and gilthead sea bream (Sparus aurata).

  2008cites this paper
• UvA-DARE ( Digital Academic Repository ) Pneumomia : an investigation of host defence mechanisms

  2007cites this paper
• Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis

  2000cites this paper
• Nitric oxide and intestinal barrier failure.

  1999cites this paper
• Endogenous mediators in sepsis and septic shock.

  1998cites this paper
• PLATELET‐ACTIVATING FACTOR (PAF) IN EXPERIMENTAL AND CLINICAL SEPSIS

  1997cites this paper
• Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate.

  1995cites this paper
• Adjunctive therapy for septic shock: a review of experimental approaches.

  1995cites this paper
• Controversies surrounding current therapies for sepsis syndrome

  1995cites this paper
• TNF and AIDS: Two sides of the same coin?

  1995cites this paper